Lees Pharmaceutical Holdings Ltd (950)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Lees Pharmaceutical Holdings Ltd (950)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH184883D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Lee's Pharmaceutical Holdings Ltd (Lee's Pharm) is a pharmaceutical company that offers clinical development services. The company produces lyophilized powder for injection, topical gel, small volume parenteral solutions and eye gel. Its product portfolio includes livaracine, yallaferon, slounase and eyprotor. Lee's Pharm's license-in products include carnitene, iron proteinsuccinylate, oral solution, aloxi, hyalofemme, prulifloxacin, declotana, combination gel, kpv peptides and papain. Its services include clinical and regulatory services, contract manufacturing, contract research, laboratory, analytical and testing services. The company operates through its sales offices located in Beijing, Shanghai and Guangzhou. Lee's Pharm is headquartered in Hong Kong.

Lee's Pharmaceutical Holdings Ltd (950)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deal Details 14

Venture Financing 14

Tragara Pharma Raises USD13 Million in Series C Financing 14

Partnerships 15

Lee's Pharma Enters into Agreement with Beijing Shenogen Pharma 15

ScinoPharm Enters into Agreement with CVie Therapeutics 16

INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 16

ScinoPharm Enters Into Co-Development Agreement With Lee's Pharma For Fondaparinux Sodium 17

ScinoPharm Announces Co-Development Agreement With Lee's Pharma For Travoprost And Bimatoprost 18

Licensing Agreements 19

Lee's Pharma Enters into Licensing Agreement with Solasia Pharma 19

Lee's Pharma Enters into Licensing Agreement with TOT Biopharm 20

Lee's Pharma Enters into Licensing Agreement with Kato Pharma 21

Laboratorios SALVAT Enters into Licensing Agreement with Lee's Pharma 22

Lee's Pharma Enters into Licensing Agreement with Solasia Pharma for Sancuso 22

Lee's Pharma Enters into Licensing Agreement with Tragara Pharma 23

China Cardiovascular Focus Enters into Licensing Agreement with Armetheon 24

Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 25

Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Thorens Cholecalciferol 26

Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Attila 27

Dilafor Enters Into Licensing Agreement With Lee's Pharma 28

Jennerex Expands Its Licensing Agreement With Lee's Pharma For Pexa-Vec 29

Dyax Enters Into Licensing Agreement With CVie Therapeutics For Kalbitor 30

Lee's Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 31

RegeneRx Biopharma Enters into Licensing Agreement with Lee's Pharma for RGN-259, RGN-352 and RGN-137 32

CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 33

CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 34

CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 36

PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 36

Nippon Shinyaku Enters into Licensing Agreement with Lee's Pharma for Gaslon N 37

Equity Offering 38

CVie Therapeutics Raises USD10 Million in Private Placement of Shares 38

Lee's Pharmaceutical Holdings Ltd-Key Competitors 40

Key Employees 41

Locations And Subsidiaries 42

Head Office 42

Other Locations & Subsidiaries 42

Recent Developments 43

Financial Announcements 43

Aug 25, 2016: Lee's Pharmaceutical Holdings: Interim Results For The Six Months Ended 30 June 2016 43

May 26, 2016: Lee's Pharmaceutical Holdings announces first quarter results for the three months ended 31 March 2016 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Lee's Pharmaceutical Holdings Ltd, Deals By Therapy Area, 2011 to YTD 2017 9

Lee's Pharmaceutical Holdings Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Tragara Pharma Raises USD13 Million in Series C Financing 14

Lee's Pharma Enters into Agreement with Beijing Shenogen Pharma 15

ScinoPharm Enters into Agreement with CVie Therapeutics 16

INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 16

ScinoPharm Enters Into Co-Development Agreement With Lee's Pharma For Fondaparinux Sodium 17

ScinoPharm Announces Co-Development Agreement With Lee's Pharma For Travoprost And Bimatoprost 18

Lee's Pharma Enters into Licensing Agreement with Solasia Pharma 19

Lee's Pharma Enters into Licensing Agreement with TOT Biopharm 20

Lee's Pharma Enters into Licensing Agreement with Kato Pharma 21

Laboratorios SALVAT Enters into Licensing Agreement with Lee's Pharma 22

Lee's Pharma Enters into Licensing Agreement with Solasia Pharma for Sancuso 22

Lee's Pharma Enters into Licensing Agreement with Tragara Pharma 23

China Cardiovascular Focus Enters into Licensing Agreement with Armetheon 24

Sorrento Therapeutics Enters into Licensing Agreement with Lee's Pharma for Anti-PD-L1 Antibody 25

Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Thorens Cholecalciferol 26

Abiogen Pharma Enters into Licensing Agreement with Lee's Pharma for Attila 27

Dilafor Enters Into Licensing Agreement With Lee's Pharma 28

Jennerex Expands Its Licensing Agreement With Lee's Pharma For Pexa-Vec 29

Dyax Enters Into Licensing Agreement With CVie Therapeutics For Kalbitor 30

Lee's Pharma Enters Into Licensing Agreement With GP Pharm For Leuprolide 31

RegeneRx Biopharma Enters into Licensing Agreement with Lee's Pharma for RGN-259, RGN-352 and RGN-137 32

CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau 33

CVie Therapeutics to Enter into Licensing Agreement with RostaQuo 34

CVie Therapeutics to Enter into Licensing Agreement with Sigma-Tau Industrie Farmaceutiche Riunite 36

PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 36

Nippon Shinyaku Enters into Licensing Agreement with Lee's Pharma for Gaslon N 37

CVie Therapeutics Raises USD10 Million in Private Placement of Shares 38

Lee's Pharmaceutical Holdings Ltd, Key Competitors 40

Lee's Pharmaceutical Holdings Ltd, Key Employees 41

Lee's Pharmaceutical Holdings Ltd, Subsidiaries 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Lee's Pharmaceutical Holdings Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com